

It Takes Two Starter Modules to Biosynthesize



PAGE 265

Nonribosomal peptides are a chemically diverse family of compounds for which important clinical and industrial applications are found. Anabaenopeptins are a family of hexapeptide protease inhibitors that contain an array of proteinogenic and nonproteinogenic amino acids as well as a conserved ureido bond. Here, Rouhiainen et al. show that these peptides are assembled on a nonribosomal peptide synthetase enzyme complex in the bloom-forming cyanobacterium *Anabaena*. Surprisingly, anabaenopeptin structural variants are produced by *Anabaena* simultaneously through the use of two separate starter modules. Anabaenopeptin synthesis constitutes a novel exception to the colinearity rule of nonribosomal peptide biosynthesis. (Figure credit: Rouhiainen et al.)

Unnatural Lysine Derivatives in Src SH2


PAGE 274

Src SH2 domain inhibitor development has proven to be challenging due to the broad specificity of the SH2 domain and the poor pharmacokinetic profile of the invariant phosphate mimics. In this study, Virdee et al. use semisynthesis to introduce unnatural lysine derivatives into the specificity-determining region of the Src SH2 domain. Protein containing the derivative diaminobutyric acid (Dab) demonstrates altered binding characteristics such that the authors observe enhanced affinity for the pYDEI phosphopeptide at the expense of affinity for the canonical pYEEI peptide. Such reengineered SH2 domains with altered specificity may find roles as research tools and therapeutics.

Covalent FGFR Inhibitors

PAGE 285

All FGFR inhibitors that have been developed for clinical use target FGFRs in a reversible manner. Here, Zhou et al. report the first irreversible inhibitor (FIIN-1) that inhibits FGFRs with a nanomolar potency and a high selectivity. FIIN-1 reacts with Cys486 positioned at the P-loop of FGFRs, and the concomitant tight ATP-competitive binding within the active site leads to a potent irreversible inhibition of the kinases. Comparable analysis with a reversible inhibitor revealed that the covalent modification not only increases the potency of the inhibitor, but also brings up a moderate inhibition of the drug-resistant gatekeeper mutant (V561 M) of FGFR1. (Figure credit: Zhou et al.)



23 Natural Tubulysins and Counting

PAGE 296

The tubulysins are a family of complex peptides that exhibit cytotoxic activity against cancer cells. Chai et al. now apply comparative analysis of the tubulysin gene clusters from two strains of myxobacteria and couple it with in vitro assays to reveal significant insights into the underlying biosynthetic pathway. In addition, the authors show that the strains make 23 novel tubulysins in total, reflecting the inherently diversity-oriented nature of the biosynthesis. These new compounds are targets for chemical synthesis, with the aim of increasing our knowledge of structure-activity relationships in this promising class of secondary metabolites.